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Abstract
Background: Stroke is an important cause of morbidity and mortality and few therapies exist thus far. Mild
hypothermia (33°C) is a promising neuroprotective strategy to improve outcome after ischemic stroke. However, its
complete mechanism of action has not yet been fully elaborated. This study is the first to investigate whether this
neuroprotection occurs through modulation of the neuroinflammatory response after stroke in a time-dependent
manner.
Methods: The Endothelin-1 (Et-1) model was used to elicit a transient focal cerebral ischemia in male Wistar rats.
In this model, the core and penumbra of the insult are represented by the striatum and the cortex respectively. We
assessed the effects of 2 hours of hypothermia, started 20 minutes after Et-1 injection on neurological outcome
and infarct volume. Furthermore, pro- and anti-inflammatory cytokine expression was determined using ELISA.
Microgliosis and astrogliosis were investigated using CD-68 and GFAP staining respectively. All parameters were
determined 8, 24, 72 hours and 1 week after the administration of Et-1.
Results: Et-1 infusion caused neurological deficit and a reproducible infarct size which increased up to 3 days after the
insult. Both parameters were significantly reduced by hypothermia. The strongest reduction in infarct volume with
hypothermia, at 3 days, corresponded with increased microglial activation. Reducing the brain temperature affected the
stroke induced increase in interleukin-1b and tumor necrosis factor a in the striatum, 8 hours after its induction, but not
at later time points. Transforming growth factor b increased as a function of time after the Et-1-induced insult and was
not influenced by cooling. Hypothermia reduced astrogliosis at 1 and 3 days after stroke onset.
Conclusions: The beneficial effects of hypothermia after stroke on infarct volume and functional outcome coincide
with a time-dependent modulation of the cytokine expression and gliosis.
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Background
Stroke is an important cause of morbidity and mortality
in industrialized countries and few therapies exist thus
far. It is generally acknowledged that many agents, pro-
ven neuroprotective in experimental models, fail in clini-
cal practice, possibly because they cannot respond to the
complex multifaceted nature of the ischemic cascade
after stroke [1-3]. Hypothermia is a well established and
robust neuroprotective treatment and has been the focus
of research as it may act on several pathways simulta-
neously [4,5]. The most common form of stroke is a tran-
sient focal cerebral ischemia attacking the Middle
Cerebral Artery (MCA) or one of its collaterals [1]. In the
endothelin-1 (Et-1) rat model, a potent vasoconstrictor is
infused in the vicinity of the MCA, thereby occluding
this vessel (>75%) during 30 minutes before gradual
reperfusion takes place [6]. The core and the penumbra
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and cortex, respectively. In this and in other MCA occlu-
sion (MCAO) models, mild hypothermia (33°C) has pro-
ven to reduce the infarct volume by half, 24 hours after
the administration of Et-1, as the result of an almost
complete recovery of the penumbra [7,8]. We also
showed that in the Et-1 model, reduction in infarct size
by hypothermic treatment coincides with decreased levels
of apoptosis and oxidative stress in the penumbra [9].
However, the influence of hypothermia on neuroinflam-
mation and neurological outcome has not yet been inves-
tigated in this model. Shortly after stroke, cytokines are
released from a variety of cells in the central nervous sys-
tem. The most important ones produced are interleukin-
1b e t a( I L - 1 b) and tumor necrosis factor alpha (TNF-a),
the former described as a pro-inflammatory cytokine and
the latter as a more pleiotropic one with neurotoxic as
well as neuroprotective properties [10-12]. Transforming
Growth Factor beta (TGF-b) on the other hand is an
anti-inflammatory cytokine that is also upregulated after
stroke and serves to protect the brain against ischemic
injury [13]. The primary source of IL-1b is activated
microglia or macrophages, followed by astrocytes. Some
production exists from neurons, endothelial cells, oligo-
dendroglia and circulating immune cells [14]. TNF-a and
TGF-b, in general, follow IL-1b’s production profile
[15,16]. Consequently, an essential role in the upregula-
tion of IL-1b,T N F - a and TGF-b can be assigned to acti-
vated microglia and macrophages [17,18]. Higher
concentrations of these cytokines further activate micro-
glia and astrocytes and a full-blown inflammatory
response develops, usually leading to an aggravation of
the damage after stroke [16,19]. It is generally accepted
that hypothermia is able to reduce the inflammatory
response after stroke [4,20]. However, there is no evi-
dence whether this reduction occurs in the core of the
insult and/or in the penumbra. In addition, short-term
effects of treatment may be different from long-term
effects. Indeed, recent literature indicates that cerebral
ischemia induces a biphasic response including a quick,
merely detrimental, inflammatory response and a slow
response, which could be beneficial. Moreover, the switch
depends on the severity of the insult. For example, at an
early stage, reactive microglia have shown neurotoxic
properties, while sustained activation appeared beneficial
to neuronal repair [16,21]. To address these essential
questions, we investigated the effects of a 2 hours mild
hypothermic treatment on microgliosis, astrogliosis and
cytokine production as a function of time up to 1 week
after an Et-1-induced insult and compared the results
with neurological outcome and infarct size at the same
time points. This study is the first to show that hypother-
mia has a modulatory effect on the neuroinflammatory
response after an Et-1-induced stroke.
Methods
The experiments were performed according to the
National Guidelines on Animal Experimentation and
approved by the Ethical Committee for Animal Experi-
mentation of the Faculty of Medicine and Pharmacy of
the Vrije Universiteit Brussel.
Surgical Procedure and the induction of stroke
Male albino Wistar rats (Charles River Laboratories,
IFFA-CREDO, Germany) weighing between 270-300 g
were treated as described previously by Van Hemelrijck
et al. (2005). Briefly, 24 hours before the induction of
the insult, the animals were anaesthetised with a mix-
ture of ketamine/diazepam (50/5 mg/kg i.p.) for implan-
tation of 2 intracerebral guides according to the atlas of
Paxinos & Watson [22]. One was positioned in the pyri-
form cortex, close to the MCA (coordinates relative to
bregma AP +0.9 mm, L +5.0 mm and V +2.8 mm), the
other one in the contralateral prefrontal cortex (AP +3.2
mm, L -3.0 mm, V +2.3 mm). Immediately after surgery,
rats received 4 mg/kg ketoprofen i.p. The next day, rats
were anaesthetised with 4% sevoflurane (Sevorane
®,
Abbott, Kent, England) and oxygen, insufflated into a
transparent chamber and were maintained under this
inhalation anaesthesia using 1.5% sevoflurane delivered
with oxygen at 0.8 L/min via a facemask throughout the
experiment. The first guide was replaced by a cannula
(CMA, 3 mm probe with removed membrane, Stock-
holm, Sweden) by which 500 pmol Et-1 (Sigma, St-
Louis, MO, USA), dissolved in Ringer’ss o l u t i o n ,a ta
rate of 1 μl/min during 6 minutes, was infused. The sec-
ond guide was substituted b yah y p o d e r m i cn e e d l e
probe (HYP-O-SLE, Omega Corporation, Stamford,
USA), adjusted to measure the brain temperature con-
tinuously in the contralateral hemisphere. These tem-
perature probes are accurate up to 0.5°C.
Experimental groups
Hypothermia was started 20 minutes after initiation of
Et-1 infusion. In 10 minutes, brain temperature was
reduced to 33.0 ± 0.5°C by spraying alcohol onto the
animal and cooling it with a fan to target temperature.
This reduced temperature was maintained for 2 hours,
after which the animals were gradually rewarmed dur-
ing 30 minutes. Subsequently, the rats were kept at 37°
C for another 30 minutes before anaesthesia was
stopped. Hypothermic animals were always compared
to normothermic rats in which the brain temperature
was kept constant at 37.0 ± 0.5°C throughout the
experiment [23]. A normothermic sham group was
included in which Ringer’s solution was infused (here-
after called sham rats). Rats were sacrificed at 8, 24, 72
or 168 hours (1 week) after the administration of Et-1.
In total, 137 animals were used for this study. Infarct
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76), while cytokine levels were measured in different
animals (n = 61).
Neurological deficit score (NDS)
Sensorimotoric outcome after stroke was assessed using
a NDS as described in Garcia et al. (1995). Six small
tests were performed and scored on the animal in order
to estimate the degree of neurological deficit after the
induction of the insult. This score resembles the NIHSS
score used in clinical practice closely. Firstly, sponta-
neous activity was determined, followed by symmetry in
the movement of the limbs, forepaw outstretching and
climbing. These last 3 parameters assessed differences in
the use of the contralateral forepaw after inducing the
insult. Finally, the equality in response to touch was
determined in the last 2 parameters: response to body
and vibrissae touch. By scoring all these different tests, a
score was given between 3 (the worst) and 18 (the best)
[24]. These parameters were assessed before and 24, 72
and 168 hours after the insult. Surgery had no effect on
the NDS (data not shown).
Infarct size
Rats were sacrificed with 6% sodium pentobarbital and
transcardially perfused with saline followed by freshly
prepared buffered 4% paraformaldehyde (250 ml in 5
minutes). The brains were dissected out and post-fixed
in the same buffer. Fifty μm thick slices were cut and
preserved on phosphate buffered saline (PBS, 0.01 M)
with sodium azide (0.1%) as a preservative. To quantify
the infarct volume stereologically, a Nissl staining was
performed on these slices every 200 μm, when mounted
onto gelatine coated glasses. Pictures of the slices at a
magnification of x1.25 were transferred to a computer.
After scaling, the marked infarcted area in mm
2 was cal-
culated using Image J (NIH, version 1.37). The infarct
volume in mm
3 was determined by multiplying these
values with the interspace. A correction for edema was
made according to the following formula: infarct area ×
(area contralateral hemisphere/area ipsilateral hemi-
sphere) [25].
Immunohistochemistry (IHC)
Phagocytic cells, originated from microglial activation
and macrophage infiltration, can be defined by CD-68
expression. Astrogliosis was measured using glial fibril-
lary acidic protein (GFAP) expression. Both were deter-
mined by IHC on 50 μm thick slices, obtained as
described above. In short, after pre-incubation with
0.01% Triton X-100, 3% hydrogen peroxide and pre-
immunized goat serum (1:5 dilution, Sigma, St-Louis,
MO, USA), brain slices were incubated overnight at 4°C,
with polyclonal mouse anti-CD-68 (1/1000 in PIG/PBS
1/5, MCA341R, AdB Serotec, Düsseldorf, Germany) or
polyclonal rabbit anti-GFAP (1/10000 in PBS, Z0334,
DakoCytomation, Glostrup, Denmark). Next, the slices
were incubated for 4 hours at room temperature with a
1/100 dilution of either sheep anti-mouse or monkey
anti-rabbit secondary antibody (NA931V and NA934V
respectively, Amersham, GE Healthcare, Buckingham-
shire, UK). Antibody binding was visualized using the
diaminobenzidine substrate chromogen kit (DakoCyto-
mation, Glostrup, Denmark). Between all incubations, a
washing step was performed with PBS/0.1% Tween-20.
For each rat, IHC protocols were performed on 3
slices taken from 0.2 mm anterior to bregma to 0.26
mm posterior to bregma [22]. In this region, interfer-
ence of the insertion of the probe to inject Et-1 was
avoided. To compare GFAP expression in sham, nor-
mothermic and hypothermic rats, the relative GFAP
staining intensity was calculated in each rat: (mean gray
value ipsilateral striatum (or cortex) - mean gray value
contralateral striatum (or cortex)), using Image J (NIH,
version 1.37) [26,27]. Calculating the difference in inten-
sity between the ipsi- and the contralateral side is
advantageous to correct for variations in circumstances
when the IHC protocols were performed. Phagocytic
cells were counted on several fields of 6 mm
2 area
(magnification x10). By using reference lines, perpendi-
cular to each other, a lattice containing 1 mm
2 squares
was placed in the same way over every brain slice. By
this technique, orientation in the slice became possible
and 3 fields consisting of 6 squares in the striatum and
cortex were counted in every brain slice at the same
place. The fields were chosen in such a way that the 3
representative parts of both the striatum and cortex
were covered. The cells in these fields were counted by
3 independent observers blinded to the experimental
design [28].
ELISA
To measure IL-1b,T N F - a and TGF-b1 protein levels
in brain homogenates, a different set of rats was sacri-
ficed following the same experimental protocol. As the
core and the penumbra of the insult are represented
by the striatum and cortex respectively, these struc-
tures were used to determine the levels of the cyto-
kines after stroke. Contra- and ipsilateral striatum and
cortex were quickly removed, accurately weighed,
snapfrozen and stored at -80°C. Next, tissues were
homogenized for 30 seconds in HEPES buffer (pH 7.4)
with 2% Protease Inhibitor cocktail (Sigma, St-Louis,
MO, USA) and subsequently sonicated for 40 seconds
(Branson Sonifier 250). After centrifugation for 30
minutes at 6720 g at 4°C (Sorvall RC5B refrigerated
superspeed centrifuge, Dupont Instruments), superna-
tants were collected and stored at -20°C until use. The
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measured using the Quantikine
® ELISA kits (R&D Sys-
tems, Abingdon, UK), according to the manufacturer’s
instructions. The kits were originally designed to deter-
mine these cytokines in rat serum, but were optimized
for brain homogenates. Only for TGF-b1, it was neces-
sary to activate the latent form before detection was
possible. This implied incubation with 1M HCl, fol-
lowed by neutralization of the samples with 1.2M
NaOH/0.5M HEPES buffer. The protein content was
determined using the Lowry method (Bio-Rad labora-
tories, California, United States).
Statistical analysis
All data are expressed as mean ± SEM. Data analysis
was performed using the statistical program Graphpad
InStat (version 3.06 Windows XP, GraphPad Software,
San Diego, California, USA). For statistical testing of
differences as a function of time, a one-way ANOVA
was used with Dunnett post-hoc test compared to
basal values or the ones obtained at 8 hours. At each
time point, a one-way ANOVA with Dunnett post-hoc
test was used to compare sham and hypothermic rats
to the normothermic ones. For statistical testing of
the infarct volume and the results of the IHC when
corrected for infarct volume, where only 2 groups
needed to be compared, an unpaired t-test was used.
The level for significance was 0.05 for all statistical
testing.
Results
Mild hypothermia reduces infarct size and improves
neurological outcome after stroke
The NDS of operated animals before administration of
Et-1 or vehicle was 17.8 ± 0.1 (mean ± SEM, n = 29).
Sham animals showed no significant changes in NDS up
t o1w e e ka f t e rR i n g e r ’s infusion. Induction by Et-1 of
focal cerebral ischemia induced a significant reduction
in NDS in normothermic animals. The hypothermic
treatment significantly improved neurological outcome
at all time points studied (Figure 1).
Normothermic rats showed a large infarct volume of
39.3 ± 2.5 mm
3, already at 8 hours after the insult
which increased further up to 54.3 ± 1.1 mm
3 at 72
hours. Between 72 hours and 1 week, the infarct size
decreased by 56% to 30.5 ± 1.7 mm
3. The hypothermic
treatment already prevented the increase in infarct size
after 8 hours. Consistent with our previous findings,
hypothermia significantly reduced the infarct size by
a l m o s th a l f( 4 4 . 4 % )a t2 4h o u rs, thereby mostly saving
the penumbral area of the infarct [9]. Even at 72 hours,
the greater part of the cortex could be salvaged by the
hypothermic treatment, resulting in a reduction of the
infarct size of 53.4% (Figure 2).
Mild hypothermia strongly affects microgliosis and
astrogliosis
When microglia become activated after brain injury,
they alter their immune phenotype and transform into
resident macrophages, thereby allowing selective staining
by anti-CD-68 (Figure 3) [16]. The way CD-68
+-cells
were counted, is illustrated in Figure 3A. Untreated ani-
mals (without surgery) showed no CD-68
+-cells (n = 4,
data not shown). In the brain slices of Et-1-treated rats,
there were no positive cells contralateral to the site of
the Et-1 injection (data not shown). In sham animals,
CD-68 expression remained low. However, 1 week after
the insult, an increase was observed in the striatum,
possibly due to the longer implantation of the probes. In
normothermic conditions, Et-1 administration induced
an increase in CD-68 expression both in the striatum
Figure 1 Evaluation of NDS post-stroke in time.E f f e c to f
hypothermic treatment on the Neurological Deficit Score (NDS) as a
function of time in sham (n = 9 at 24 and 72 hours and n = 5 at
168 hours), normothermic (n = 12 at 24 and 72 hours and n = 7 at
168 hours) and hypothermic (n = 14 at 24 and 72 hours and n = 8
at 168 hours) animals. *Significantly different (p < 0.05) from 0 hours
as determined by one-way ANOVA followed by Dunnett post-hoc
test.
§Significantly different (p < 0.05) from normothermic rats as
determined by one-way ANOVA followed by Dunnett post-hoc test.
Figure 2 Hypothermia attenuates the Et-1-induced infarct size
up to 1 week. Effect of hypothermia on the Et-1-induced infarct
volume as a function of time in normothermic (n = 4, 10, 5 and 7
at 8, 24, 72 and 168 hours respectively) and hypothermic (n = 5, 8,
7 and 8 at 8, 24, 72 and 168 hours respectively) animals. Data are
shown as mm
3 (mean ± SEM). *Significantly different compared to
the infarct volume at 8 hours as determined by one-way ANOVA
with Dunnett post-hoc test.
§Significantly different (p < 0.05) from
normothermic rats as determined by the unpaired t-test.
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Page 4 of 12Figure 3 Hypothermia causes time-dependent changes on CD-68 expression after stroke. (A) shows the 3 fixed fields in the striatum and
the cortex in which CD-68
+-cells were counted using a lattice. The reference lines are represented in red. The phagocytic cells determined by
expression of CD-68 in a normothermic and hypothermic rat at 72 hours after the administration of Et-1 or Ringer’s are shown in (B) and (C)
respectively. The graphs below show the overall expression in the striatum (D) and the cortex (E) separately. Data are expressed as the number
of cells/mm
2 and are shown as the mean ± SEM. There was no binding of the second antibody in the absence of the primary antibody (data
not shown). *Significantly different (p < 0.05) compared to the results at 8 hours as determined by one-way ANOVA with Dunnett post-hoc test.
Furthermore,
§normothermic rats (n = 4, 8, 5 and 8 at 8, 24, 72 and 168 hours respectively) were compared to sham rats (n = 4 at 8, 24 and 72
hours and n = 5 at 168 hours) and hypothermic rats (n = 5, 6, 6 and 8 rats at 8, 24, 72 and 168 hours respectively) using one-way ANOVA with
Dunnett post-hoc test.
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treatment influenced CD-68 expression differently
depending on the time after the insult. At 24 hours,
hypothermia attenuated CD-68
+-cells in the cortex.
However, 72 hours after the insult, hypothermic treat-
ment significantly enhanced CD-68 expression about 5-
fold compared to normothermic animals in both stria-
tum and cortex.
Untreated animals displayed equal levels of GFAP
expression in both hemispheres (data not shown). GFAP
expression in the contralateral hemisphere was not
affected by any treatment. As observed for CD-68, low
expression of GFAP was present in the ipsilateral hemi-
sphere of sham animals. In the normothermic animals,
GFAP expression in the striatum peaked at 24 hours
after the insult, followed by a gradual decline. Hypother-
mia significantly suppressed the expression of GFAP in
the striatum at 24 hours and in the cortex at 24 and 72
hours after the insult (Figure 4).
Correction of the CD-68 and GFAP staining data for
infarct size shows that some of the observed effects of
hypothermia in the striatum or cortex are modulated
by the infarct size, especially at early time points after
the insult. Indeed, CD-68
+-cells which were decreased
or increased by the hypothermic treatment at 8 hours
in the striatum or cortex respectively, show an overall
increase in microglial activation. At 24 hours after the
insult, the hypothermia-induced reduction in CD-68
+-cells is no longer observed after correction of the
infarct size. On the other hand, the marked increase in
CD-68 expression at 72 hours after hypothermia is
even stronger after correction (Figure 5A). In contrast,
t h ed e c r e a s ei nG F A Pe x p r e s s i o nb yt h eh y p o t h e r m i c
treatment at 24 and 72 hours is reduced after correc-
tion. However, the attenuation at 72 hours is still sig-
nificant, indicating that the reduction in GFAP
expression is in part independent of the reduction in
infarct size (Figure 5B).
Mild hypothermia affects the early production of pro-
inflammatory cytokines in the ipsilateral striatum and
cortex
Basal levels of IL-1b and TNF-a were not detectable.
Therefore, at 0 hours, their level was equalled to the
detection limit (IL-1b: 11.5 pg/ml, TNF-a:4 . 7p g / m l )
and divided by the protein content of untreated animals,
in order to perform statistical analysis (Figure 6).
IL-1b levels were significantly increased in the sham
rats, 8 hours after the infusion of Ringer’s solution, both
in the striatum and the cortex. Afterwards they
decreased back to basal levels (Striatum: 1.2 ± 0.1 pg/
mg protein, Cortex: 1.3 ± 0.04 pg/mg protein, n = 10).
A similar profile was observed after Et-1 administration
in normothermic rats. IL-1b levels were significantly
higher than those in the sham animals except at 8 hours
in the cortex. One week after the insult, IL-1b was no
longer detectable in all treatment protocols. Hypother-
mia attenuated the IL-1b increase at all time points stu-
died. However, a statistical significant difference was
only observed at the 8 hour time point in the ipsilateral
striatum.
In all treatment protocols, TNF-a was only detected
up to 24 hours after the insult. Furthermore, TNF-a
levels were significantly lower in the cortex compared to
the striatum (Wilcoxon-matched pairs test, p < 0.05),
which is consistent with literature findings [11]. TNF-a
levels were slightly increased in sham and normothermic
rats until 24 hours after the administration of Ringer’s
solution compared to basal levels (Striatum: 0.5 ± 0.01
pg/mg protein, Cortex: 0.5 ± 0.02 pg/mg protein, n =
10). Hypothermia significantly enhanced TNF-a levels
immediately after the insult in the striatum. In the cor-
tex, this increase did not reach statistical significance. At
the 24 hours time point, hypothermia had no significant
effect on the Et-1-induced TNF-a levels compared to
normothermic animals.
TGF-b1 was only determined in the cortex as the
small amount of sample of the striatum hampered its
measurement in this structure. Besides, histology
showed that hypothermia primarily salvages the penum-
bra (cortex) [9]. Basal levels of TGF-b1 were detectable:
12.1 ± 1.0 pg/mg protein (n = 10). A gradual increase in
TGF-b1 was observed up to 72 hours after the insult.
There was no significant difference observed between
sham, normothermic or hypothermic rats. Thus,
hypothermia had no effect on the possible beneficial
effects of TGF-b1 in the cortex.
Discussion
It is generally accepted that hypothermia improves neu-
rological outcome and reduces inflammation in animal
models of focal cerebral ischemia, but no elaborate stu-
dies exist in the Et-1 model [7,20,28,29]. It is, however,
important to investigate inflammation after stroke in
v a r i o u sa n i m a lm o d e l sa st h et y p eo fm o d e lu s e dt o
induce cerebral ischemia will partially influence the
inflammatory response after stroke. The Et-1 model is a
good alternative for several reasons. First, to induce the
insult, there is no damage to the cerebral vasculature.
Secondly, the reperfusion after stroke is gradual which is
most common in a clinical situation. Finally, in the Et-1
model, mechanical manipulations are minimized which
is ideal for investigating inflammation [25,30]. Further-
more, there is need for additional studies looking at the
effects of hypothermia on neuroinflammation at differ-
ent time points after the insult. The latter is especially
relevant as treatments may exert different effects on
early versus late inflammatory responses [21]. In this
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neuroinflammation at different time points up to 1 week
after the insult were investigated.
A reduction of infarct size by application of mild
hypothermia in the Et-1 model has been reported before
[9]. Here we show for the first time that this reduction
coincides with an improvement in neurological outcome
which is sustained for at least one week. Our study con-
firms the general notion that 2 hours of mild hypother-
mia, started 20 minutes after stroke onset, exerts anti-
inflammatory effects [28,29]. This is reflected by our
observation that hypothermia impairs IL-1b production
Figure 4 Hypothermia reduces GFAP staining 24 hours after an Et-1-induced insult. Activation of astrocytes as determined by the
expression of GFAP in a sham (A), normothermic (B) and hypothermic (C) rat, 24 hours after the administration of Et-1 or Ringer’s solution. The
graphs below show the overall expression in striatum (D) and cortex (E) separately in sham (n = 4 at 8, 24 and 72 hours and n = 5 at 168
hours), normothermic (n = 4, 6, 5 and 6 at 8, 24, 72 and 168 hours respectively) and hypothermic (n = 5, 6, 7 and 8 at 8, 24, 72 and 168 hours
respectively) rats. *Significantly different (p < 0.05) compared to 8 hours as determined by one-way ANOVA with Dunnett post-hoc test.
§Significantly different (p < 0.05) from normothermic rats as determined by one-way ANOVA with Dunnett post-hoc test.
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is the first to show that hypothermia can enhance CD-
68 expression in the striatum and cortex at later time
points and augment the expression of TNF-a in the
striatum. In the following sections, we will discuss the
role of neuroinflammation in the neuroprotective effects
of hypothermia.
The neuroinflammatory response in the Et-1 model
As in other MCAO models, we observed the largest
infarct volume at 3 days after the insult, followed by a
significant decrease in infarct size at 1 week. This sug-
gests that regions with no living cells (Nissl-negative) at 3
days after stroke onset (especially the core of the insult)
become infiltrated by resident and/or blood-borne
macrophages after 1 week [25]. Indeed, these cells clear
up the necrotic cell debris and may therefore be responsi-
ble for the smaller measured infarcted area. Our observa-
tion that CD-68 expression peaks at 1 week after the
administration of Et-1, sup p o r t st h i sh y p o t h e s i s .O u r
d a t aa r ei nl i n ew i t ht h o s eo fZ h a n get al. (1997) who
also observed an increase in this microglial activation up
to 166 hours after a 2-hour MCAO [31]. The phagocytic
activity of macrophages in the necrotic tissue is consid-
ered to be potentially protective [25,31]. Our results are
consistent with this notion, as we observed a reduced
infarct volume at 1 week after administration of Et-1
which coincides with peak levels of CD-68
+-cells. More-
over, the neuroprotective influence of activated microglia
is suggested by the strong reduction in infarct volume
with hypothermia at 3 days, which corresponded with
increased levels of CD-68 expression. Neuroprotective
effects of microglia have been demonstrated in a mouse
model for transient MCAO by selective ablation of
proliferating microglia [32]. Furthermore, in a recent
study by Narantuya et al. (2010), intravenous administra-
tion of human microglial cells after a 90 minutes MCAO
in rats, improved neurological outcome and reduced
infarct size [33]. However, microglia may also exert detri-
mental effects via the production of inflammatory cyto-
kines. For instance, IL-1b is generally accepted to be a
pro-inflammatory cytokine that will enhance cell damage,
whereas TNF-a is considered to be a neuromodulator
which may exert protective as well as detrimental effects
[10-12,16]. Protective effects may be the result of induc-
tion of neutrophil apoptosis and their engulfment by
macrophages, an effect which seems beneficial as this
phagocytosis prevents the lytic release of cytotoxic con-
tents into the surrounding tissue [25,34]. Alternatively,
TNF-a may protect neurons from apoptosis through
activation of NF-B [11,35]. In a permanent MCAO
mouse model, Legos et al. (2000) suggested that produc-
tion of IL-1b shows a biphasic release pattern with a first
peak only a few minutes to 1 hour after stroke onset with
a return to basal values at 8 hours and a second peak
from 12 hours to 3 days [36]. In our study, we did not
observe a biphasic release pattern for IL-1b. These differ-
ences could be due to the different models used to study
the temporal profile of IL-1b after stroke. TGF-b1, an
overall anti-inflammatory cytokine, is upregulated after
stroke. It controls proliferation, differentiation, apoptosis
and migration of varying cells, like neurons and astro-
cytes [37]. In contrast to IHC, ELISA on brain homoge-
nates allows easy detection of the latent form of TGF-b1
[13]. We observed a consistent increase of TGF-b1a sa
function of time. These results confirm literature find-
ings, which show that TGF-b1 increases up to 1 week
after the insult in rats and mice [17,37].
Figure 5 Microgliosis and astrogliosis corrected for the infarct volume. Graphs (A) and (B) represent the data of the CD-68 and GFAP
staining respectively, when corrected for the infarcted area. All infarct volumes were expressed as a percentage of the infarct size in
normothermic rats at 8 hours after the infusion of Et-1. The data show that the observed changes in microgliosis and astrogliosis in this study
cannot be solely ascribed to differences in infarcted area. *Significantly different (p < 0.05) compared to 8 hours as determined by one-way
ANOVA with Dunnett post-hoc test.
§Significantly different (p < 0.05) from normothermic rats as determined by the unpaired t-test.
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Page 8 of 12Figure 6 Determination of cytokine expression after stroke in time and the effect of hypothermia. Effect of hypothermic treatment on
the protein levels of cytokines as a function of time after Et-1 administration for sham, normothermic and hypothermic rats. Levels are
expressed as pg/mg protein and are shown as mean ± SEM. Graphs (A) and (B) show the levels of IL-1b at several time points after the
administration of Et-1 for striatum and cortex respectively, (C) and (D) for TNF-a and (E) represent the levels of TGF-b in the cortex. The number
of rats used to determine the levels for IL-1b and TGF-b were in the sham group: 6, 4 and 4 at 8, 24 and 72 hours; in the normothermic group:
6 at 8, 24 and 72 hours; and in the hypothermic group: 6, 6 and 5 at 8, 24 and 72 hours. The number of rats used to determine the levels for
TNF-a was in the sham group: 6 at 8 and 24 hours; in the normothermic group: 5 and 6 at 8 and 24 hours; and in the hypothermic group: 5
and 6 at 8 and 24 hours. Basal levels were measured in rats that underwent no treatment (n = 10) *Significantly different (p < 0.05) from basal
levels determined by one-way ANOVA with Dunnett post-hoc test.
§Significantly different (p < 0.05) from normothermic rats as determined by
one-way ANOVA with Dunnett post-hoc test.
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Page 9 of 12Astrocytes are essential elements of the blood brain
barrier, they maintain extracellular homeostasis and pro-
duce trophic factors [38]. Nowicka et al. (2008)
described the temporal profile of astrogliosis after stroke
in the photothrombosis model. It started with a massive
astroglial response in the core of the lesion 4 hours
after the trauma and activation was observed up to 28
days after stroke onset [39]. Our results are similar with
massive astrogliosis peaking at 1 day. Afterwards, it
declines again, but stays visible up to 1 week. Somewhat
different are the results from a study by Zhu et al.
(2000) in a transient forebrain ischemia model (with 10
minutes occlusion) which showed slight activity 1 day
after the insult and peak activity at 4 days. However
these results were obtained from brain slices from the
hippocampus and not from the striatum [37].
Two hours of mild hypothermia affects the
neuroinflammatory response observed after the
administration of Et-1
Mild hypothermia improved functional and neurological
outcome up to 1 week after stroke. It was important to
consider the evolution of both functional recovery and
brain tissue salvation, to see if a short hypothermic period
can reduce damage long-term after an insult [7,40-42]. In
this study, the infarct volume in hypothermic rats never
reached the volume observed in normothermic rats at 8
hours. Furthermore, the increase in infarct volume in nor-
mothermic animals between 8 and 72 hours was also
absent in hypothermic rats. In addition, the improvement
in neurological outcome at 24 hours was sustained for at
least 6 days and even slightly increased.
The inhibition of IL-1b expression confirms that
hypothermia reduces inflammation [7]. In contrast to
IL-1b,T N F - a was increased in the ipsilateral striatum
after application of hypothermia at 8 hours after the
insult. Indeed, at that time point, CD-68 expression in
the striatum was decreased, while GFAP levels were
increased more than 2-fold in the striatum of hypother-
mic rats, although not significantly (p = 0.07). It is also
possible that hypothermia exerts differential effects on
individual genes. This implies that certain genes, such as
those for TNF-a, are more strongly stimulated than
other genes (e.g. GFAP). Since inhibition of TNF-a
activity in a murine MCAO model decreased infarct
size, it could be that the increase in TNF-a expression
exerts negative effects in our model [43]. Therefore, we
have to consider the possibility that the effect of
hypothermia is a cumulative outcome of negative and
positive effects. However, the influence of TNF-a
strongly depends on the relative expression of type I
and type II TNF receptors (TNFR1 and TNFR2, respec-
tively) which trigger different signal transduction path-
ways and cellular effects. For example, a null mutation
of TNFR1 in a murine MCAO model resulted in
increased neuronal damage compared to controls and
mice with a TNFR2 null mutation [35]. Interestingly,
Lotocki et al. (2006) found that after traumatic brain
injury, TNFR1 is highly upregulated after 15 minutes
and hypothermia is able to reduce this overexpression
so soon after the injury [44].
Whereas the results on CD-68 expression, when cor-
rected for infarct volume, suggest that the inhibitory
effect of hypothermia observed in the cortex at 1 day
after the insult, is due to reduced infarct volume, the
increase in phagocytic cells at 3 days is not. Indeed, CD-
68 expression is significantly increased in hypothermic
rats at 3 days after the Et-1-induced stroke. Other
groups have shown that after 3 days, macrophages pha-
gocytose necrotic cell debris and facilitate plasticity
[21,25]. Therefore, the increase in CD-68
+-cells at 3
days could point to a beneficial increase in macro-
phages. However, Wang et al. (2002) observed a signifi-
cant decrease in CD-68 expression with hypothermic
treatment 3 days after the induction of a 2 hours lasting
ischemia. The differences in occlusion time (2 hours
versus 30 minutes) and onset of the hypothermic treat-
ment (immediately versus a 20 minutes delay) could
explain this discrepancy [20,28]. Furthermore, our
observation that the hypothermic treatment still signifi-
cantly increases the level of CD-68 staining at 3 days
after the insult may also explain why delayed hypother-
mia can still be effective [45-47]. Moreover, the bidirec-
tional data on CD-68 expression, when striatum and
cortex are analyzed individually, may be explained by
assuming that hypothermia exerts a short- and long-
term effect on microglial activation. The short-term
effect would consist of a reduction in infarct size and a
concomitant decrease in microglial activation in the
striatum, while the long-term effect comprises an
increase in CD-68 expression at 3 days after the admin-
istration of Et-1, possibly as a result of enhanced TNF-a
production. Alternatively, because CD-68 is also present
on macrophages, the long-term effect (observed at 3
days after the insult) may also be due to increased
expression of chemokines leading to enhanced infiltra-
tion of macrophages from the periphery.
Astrogliosis is reduced in hypothermic animals 1 and 3
days after the administration of Et-1. Although the
changes in GFAP expression after application of hypother-
mia seem partially dependent on the reduced infarct
volume at early time points after the insult, the combined
results suggest that hypothermia exerts differential effects
on the activation of microglia and astrocytes.
In the end, the balance between pro- and anti-inflam-
matory cytokines will determine the positive or negative
influence of a neuroprotective agent. TGF-b1 is a neuro-
protective compound and exogenous administration of
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Page 10 of 12TGF-b1 has been shown to decrease the infarct volume
after stroke [48], but the spontaneous endogenous
increase in TGF-b1 after stroke is not enough to cause
effective neuroprotection [ 4 9 ] .H o w e v e r ,h y p o t h e r m i a
had no effect on the Et-1-induced increase in TGF-b1.
Our study clearly demonstrates that hypothermia does
not merely lead to a delay of events in the ischemic cas-
cade. In contrast, specific up- or down-regulation of dif-
ferent cytokines occurs and these events take place at
specific time points after hypothermia. Moreover, to
optimize the application of hypothermia, the expression
of genes (e.g. cytokines, chemokines, neurotrophic fac-
tors) and their role in ischemic damage or neuroprotec-
tion should be investigated.
In order to translate the optimal treatment protocol to
the clinic, effects of hypothermia on peripheral immune
suppression should also be taken into account. Immune
suppression by either stroke or hypothermia may lead to
an increased incidence of infections and a higher mor-
tality [50]. However, the possibility that the inhibition of
the immune response after stroke may be beneficial due
to reduction of inflammatory responses in the brain
should also be considered. Indeed, treatments with anti-
inflammatory drugs have been shown to attenuate
infarct size after experimental stroke [51]. Thus, combi-
nation of hypothermia with anti-infectious therapies
may lead to less mortality and improved outcome in the
hypothermic group in clinical settings.
Conclusions
This study is the first to examine the neuroinflammatory
response as a function of time after hypothermia in the
Et-1 model for transient focal cerebral ischemia. Up to 1
week after the insult, hypothermia improved neurological
outcome and significantly reduced infarct volume after
the administration of Et-1. We suggest that hypothermia
affects the early changes in the levels of pro-inflamma-
tory cytokines after Et-1 administration. The pro-inflam-
matory IL-1b levels were reduced by hypothermic
treatment, whereas those of TNF-a increased soon after
the injection of Et-1. The current study is the first to
show that phagocytic cells may play a dual role after
stroke since the most prominent protection observed 3
days after the insult was associated with increased CD-68
expression. On the other hand, astrogliosis was reduced
by the hypothermic treatment. Our data suggest that
hypothermia modulates neuroinflammation after stroke,
possibly allowing the therapeutic time window for other
treatments (e.g. neuroprotective agents, anti-inflamma-
tory drugs) to be extended after stroke.
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